Linden Thomas Advisory Services LLC Has $884,000 Holdings in Xencor, Inc. (NASDAQ:XNCR)

Linden Thomas Advisory Services LLC trimmed its position in Xencor, Inc. (NASDAQ:XNCR) by 2.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,653 shares of the biopharmaceutical company’s stock after selling 1,037 shares during the quarter. Linden Thomas Advisory Services LLC owned approximately 0.07% of Xencor worth $884,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in XNCR. Armistice Capital LLC raised its stake in Xencor by 65.7% in the 3rd quarter. Armistice Capital LLC now owns 1,478,000 shares of the biopharmaceutical company’s stock worth $29,782,000 after purchasing an additional 586,000 shares in the last quarter. Primecap Management Co. CA increased its stake in Xencor by 5.6% in the third quarter. Primecap Management Co. CA now owns 8,184,206 shares of the biopharmaceutical company’s stock valued at $164,912,000 after acquiring an additional 433,354 shares during the last quarter. abrdn plc acquired a new position in Xencor during the fourth quarter valued at approximately $3,726,000. Hudson Bay Capital Management LP lifted its stake in Xencor by 144.7% during the third quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company’s stock worth $4,685,000 after purchasing an additional 137,500 shares during the last quarter. Finally, TD Asset Management Inc boosted its holdings in shares of Xencor by 57.6% in the 3rd quarter. TD Asset Management Inc now owns 180,164 shares of the biopharmaceutical company’s stock valued at $3,630,000 after purchasing an additional 65,825 shares in the last quarter.

Insider Buying and Selling at Xencor

In other news, VP John R. Desjarlais sold 54,108 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the transaction, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Xencor news, VP John R. Desjarlais sold 54,108 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now owns 161,675 shares of the company’s stock, valued at approximately $3,133,261.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Kurt A. Gustafson sold 14,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $23.18, for a total transaction of $324,520.00. Following the completion of the sale, the director now directly owns 6,007 shares in the company, valued at $139,242.26. The disclosure for this sale can be found here. Insiders sold a total of 101,351 shares of company stock valued at $2,152,417 in the last three months. Company insiders own 4.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on XNCR shares. StockNews.com upgraded Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. BMO Capital Markets dropped their target price on Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Wedbush reduced their price target on Xencor from $36.00 to $34.00 and set an “outperform” rating on the stock in a report on Wednesday, February 28th. Mizuho dropped their price target on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 22nd. Finally, BTIG Research decreased their price objective on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Xencor currently has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Xencor Stock Performance

Shares of Xencor stock opened at $19.23 on Friday. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 0.02. The stock has a fifty day simple moving average of $22.10 and a 200 day simple moving average of $20.34. Xencor, Inc. has a 12-month low of $16.49 and a 12-month high of $28.96.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). The company had revenue of $44.70 million during the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. Xencor’s revenue was up 106.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.20) earnings per share. Sell-side analysts expect that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.